Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium animalis BLa80 + bifidobacterium longum BL21 + lacticaseibacillus rhamnosus LRa05
- Development stage
- Unknown
- Lead developer
- Wecare Probiotics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This probiotic combination consists of three specific bacterial strains: *Bifidobacterium animalis* subsp. *lactis* BLa80, *Bifidobacterium longum* BL21, and *Lacticaseibacillus rhamnosus* LRa05 (formerly *Lactobacillus rhamnosus*). Developed by Wecare Probiotics, this consortium is designed to modulate the gut microbiota, enhance intestinal barrier function, and support systemic immune responses. The strains were selected for their high acid and bile salt resistance, as well as their ability to adhere to the intestinal mucosa and produce short-chain fatty acids (SCFAs). Clinical investigations have primarily focused on the combination's efficacy in improving gastrointestinal health, specifically addressing constipation and dysbiosis, while also exploring potential benefits in allergic rhinitis and immune function regulation.
- Other names
- Bifidobacterium animalis subsp. lactis BLa80 + Bifidobacterium longum BL21 + Lacticaseibacillus rhamnosus LRa05Wecare Probiotics Consortium
Beyond the preview
Go deeper on bifidobacterium animalis BLa80 + bifidobacterium longum BL21 + lacticaseibacillus rhamnosus LRa05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium animalis BLa80 + bifidobacterium longum BL21 + lacticaseibacillus rhamnosus LRa05.